NZ585137A - Tropane compounds useful as hsp90 inhibitors - Google Patents

Tropane compounds useful as hsp90 inhibitors

Info

Publication number
NZ585137A
NZ585137A NZ585137A NZ58513708A NZ585137A NZ 585137 A NZ585137 A NZ 585137A NZ 585137 A NZ585137 A NZ 585137A NZ 58513708 A NZ58513708 A NZ 58513708A NZ 585137 A NZ585137 A NZ 585137A
Authority
NZ
New Zealand
Prior art keywords
amino
endo
oct
azabicyclo
methyl
Prior art date
Application number
NZ585137A
Other languages
English (en)
Inventor
Kenneth D Rice
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of NZ585137A publication Critical patent/NZ585137A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
NZ585137A 2007-10-25 2008-10-27 Tropane compounds useful as hsp90 inhibitors NZ585137A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68707P 2007-10-25 2007-10-25
PCT/US2008/012221 WO2009055077A1 (en) 2007-10-25 2008-10-27 Tropane compounds

Publications (1)

Publication Number Publication Date
NZ585137A true NZ585137A (en) 2012-07-27

Family

ID=40287869

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ585137A NZ585137A (en) 2007-10-25 2008-10-27 Tropane compounds useful as hsp90 inhibitors

Country Status (26)

Country Link
US (1) US8012956B2 (enExample)
EP (1) EP2074120B1 (enExample)
JP (2) JP5476307B2 (enExample)
KR (1) KR101578792B1 (enExample)
CN (1) CN101910168B (enExample)
AT (1) ATE459622T1 (enExample)
AU (1) AU2008317262B2 (enExample)
BR (1) BRPI0818893B8 (enExample)
CA (1) CA2703477C (enExample)
CO (1) CO6321232A2 (enExample)
CY (1) CY1110648T1 (enExample)
DE (1) DE602008000754D1 (enExample)
DK (1) DK2074120T3 (enExample)
EA (1) EA018999B1 (enExample)
ES (1) ES2342348T3 (enExample)
HR (1) HRP20100292T1 (enExample)
IL (1) IL205202A0 (enExample)
MX (1) MX2010004493A (enExample)
NZ (1) NZ585137A (enExample)
PL (1) PL2074120T3 (enExample)
PT (1) PT2074120E (enExample)
RS (1) RS51346B (enExample)
SG (1) SG2012079653A (enExample)
SI (1) SI2074120T1 (enExample)
WO (1) WO2009055077A1 (enExample)
ZA (1) ZA201002987B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2231666B1 (en) * 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
AU2011236933A1 (en) 2010-04-05 2013-05-02 Shionogi & Co., Ltd. Cephem compound having catechol group
EP2640366A2 (en) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
EP2740474A1 (en) 2012-12-05 2014-06-11 Instituto Europeo di Oncologia S.r.l. Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
WO2014107718A2 (en) * 2013-01-07 2014-07-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Heat shock protein (hsp) inhibition and monitoring effectiveness thereof
CA2921294C (en) 2013-08-21 2023-05-16 Alios Biopharma, Inc. Antiviral compounds
MX2016006457A (es) * 2013-11-18 2017-01-06 Del Mar Pharmaceuticals Analisis de cromatografia liquida de alto rendimiento (hplc) de impurezas en dianhidrogalactitol.
MX375102B (es) 2014-05-30 2025-03-06 Ieo St Europeo Di Oncologia S R L Compuestos de ciclopropilamina como inhibidores de histona demetilasa
EP2949648A1 (en) 2014-05-30 2015-12-02 IEO - Istituto Europeo di Oncologia Srl Cyclopropylamine derivatives as histone demethylase inhibitors
WO2016061253A1 (en) 2014-10-14 2016-04-21 Exelixis, Inc. Drug combination to treat melanoma
EP3322450A1 (en) * 2015-07-16 2018-05-23 Akuru Pharma AB Detection and treatment of renal cell carcinoma with a slc6a3 ligand linked to a label, cytotoxic or immunomodulatory group
WO2018155260A1 (ja) * 2017-02-23 2018-08-30 株式会社Ihi Ｏｈラジカル検出プローブ、ｏｈラジカル測定装置、および、ｏｈラジカル測定方法
CN108164529B (zh) * 2017-12-25 2020-04-24 三峡大学 一种小分子抑制剂sld9059及其在制药中的应用
ES2905568T3 (es) 2018-01-10 2022-04-11 Allinky Biopharma Compuestos de tetrahidroisoquinolina
WO2020206608A1 (en) 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
CN111825702A (zh) * 2019-04-22 2020-10-27 成都科岭源医药技术有限公司 一种氮杂*并吲唑类衍生物及其制备方法和用途
CN110698395B (zh) * 2019-10-22 2021-05-25 杭州百诚医药科技股份有限公司 一种托吡司特的中间体的制备方法
CN112920078A (zh) * 2019-12-05 2021-06-08 武汉珈汇精化科技有限公司 一种制备4-氰基苯甲酸甲酯的方法和一种制备4-氰基苯甲酸的方法
TW202136238A (zh) * 2020-01-06 2021-10-01 大陸商廣東東陽光藥業有限公司 RORγt抑制劑及其製備方法和用途
AU2021362975A1 (en) * 2020-10-14 2023-05-25 Ranok Therapeutics (Hangzhou) Co. Ltd. Methods and compositions for targeted protein degradation
CN114591192B (zh) * 2020-12-04 2024-06-21 江西仰立新材料有限公司 一种n-环丙甲基苯胺类化合物的制备方法
WO2022132679A1 (en) * 2020-12-18 2022-06-23 Merck Sharp & Dohme Corp. Amido-substituted pyridyl compounds and methods of use thereof for the treatment of herpesviruses
CN112707809B (zh) * 2020-12-30 2023-08-29 丽珠集团新北江制药股份有限公司 一种制备噁唑啉杀虫剂氟雷拉纳中间体的方法
ES3036671T3 (en) * 2021-07-26 2025-09-23 Zoetis Services Llc Serotonin 5-ht2b inhibitory compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101641A3 (en) 1982-07-22 1984-03-28 Beecham Group Plc Sulfonylamino-aza-bicyclo-alkyl derivatives
FR2738569B1 (fr) * 1995-09-12 1997-11-28 Pf Medicament Nouveaux derives naphtamide de 3 beta-amino azabicyclo octane ou nonane, leur procede de preparation, leur utilisation a titre de medicament antipsychotique
AU717744B2 (en) 1996-01-15 2000-03-30 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
HUP0202001A2 (hu) * 2002-06-14 2005-08-29 Sanofi-Aventis DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
ES2329133T3 (es) * 2003-05-28 2009-11-23 Theravance, Inc. Compuestos azabicicloalcanicos como antagonistas de receptores de muscarinicos.
WO2004113334A1 (en) * 2003-06-24 2004-12-29 Neurosearch A/S Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
ES2295924T3 (es) 2003-10-03 2008-04-16 Pfizer, Inc. Derivados de tropano imidazopirina sustituidos con actividad antagonista de los receptores ccr5 para el tratamiento de vih y de la inflamacion.
GB0323236D0 (en) * 2003-10-03 2003-11-05 Pfizer Ltd Chemical compounds
WO2005095380A1 (ja) * 2004-03-31 2005-10-13 Nippon Soda Co., Ltd. 環状アミン化合物および有害生物防除剤
FR2873693B1 (fr) * 2004-07-29 2006-09-15 Sanofi Synthelabo Derives d'amino-tropane, leur preparation et leur application en therapeutique
EP1838705A2 (en) 2005-01-13 2007-10-03 Neurosearch A/S 3,8-substituted 8-aza-bicyclo [3.2.1] octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
EP1932844B1 (en) * 2005-10-06 2015-09-02 Nippon Soda Co., Ltd. Cross-linked cyclic amine compounds and agents for pest control
US7994094B2 (en) * 2006-09-01 2011-08-09 Otsuka Agritechno Co., Ltd. N-pyridylpiperidine compound, method for producing the same, and pest control agent

Also Published As

Publication number Publication date
CO6321232A2 (es) 2011-09-20
AU2008317262A1 (en) 2009-04-30
SG2012079653A (en) 2014-05-29
MX2010004493A (es) 2010-06-11
EA201070519A1 (ru) 2010-12-30
EA018999B1 (ru) 2013-12-30
JP5745021B2 (ja) 2015-07-08
PL2074120T3 (pl) 2010-08-31
EP2074120B1 (en) 2010-03-03
ZA201002987B (en) 2011-02-23
US8012956B2 (en) 2011-09-06
KR20100090782A (ko) 2010-08-17
JP5476307B2 (ja) 2014-04-23
IL205202A0 (en) 2010-12-30
KR101578792B1 (ko) 2015-12-21
BRPI0818893B1 (pt) 2021-02-02
RS51346B (sr) 2011-02-28
ES2342348T3 (es) 2010-07-05
WO2009055077A1 (en) 2009-04-30
BRPI0818893A2 (pt) 2015-05-05
SI2074120T1 (sl) 2010-06-30
US20090163471A1 (en) 2009-06-25
JP2011500815A (ja) 2011-01-06
ATE459622T1 (de) 2010-03-15
DK2074120T3 (da) 2010-06-14
CA2703477A1 (en) 2009-04-30
HK1129390A1 (en) 2009-11-27
JP2014070077A (ja) 2014-04-21
CY1110648T1 (el) 2015-06-10
EP2074120A1 (en) 2009-07-01
CN101910168A (zh) 2010-12-08
PT2074120E (pt) 2010-06-15
AU2008317262B2 (en) 2013-12-19
CA2703477C (en) 2016-10-11
HRP20100292T1 (hr) 2010-06-30
BRPI0818893B8 (pt) 2021-05-25
CN101910168B (zh) 2014-07-30
DE602008000754D1 (de) 2010-04-15

Similar Documents

Publication Publication Date Title
EP2074120B1 (en) Tropane compounds
AU2017336523B2 (en) Calpain modulators and therapeutic uses thereof
US8440663B2 (en) 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use
AU2014348191B2 (en) Tetrahydroquinoline compositions as BET bromodomain inhibitors
JP6611358B2 (ja) 癌治療のためのｆａｓｎ阻害剤として有用なベンズアミド誘導体
AU2013353542B2 (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer
CN105814051B (zh) 用作tnf活性调节剂的四氢咪唑并吡啶衍生物
TW202235072A (zh) 用於治療ｔｒｐｍ３介導病症之雜環衍生物
CA2884355C (en) Imidazolin-5-one derivative useful as fasn inhobitors for the treatment of cancer
EA026201B1 (ru) Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
KR20150135794A (ko) 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 ｐｈｄ의 저해제로서의 그의 용도
EP1937639B1 (en) Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)
WO2022112345A1 (en) Aryl derivatives for treating trpm3 mediated disorders
CA2718038A1 (en) Azabicyclo [3.2.1] octyl derivatives as 11 beta-hsd1 modulators
US20130244999A1 (en) Substituted Heterocyclic Compounds
HK1129390B (en) Tropane compounds
WO2019125838A1 (en) Purine inhibitors of human phosphatidylinositol 3-kinase delta

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2016 BY CPA GLOBAL

Effective date: 20150911

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2017 BY CPA GLOBAL

Effective date: 20160923

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2018 BY CPA GLOBAL

Effective date: 20170914

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2019 BY CPA GLOBAL

Effective date: 20181004

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2020 BY CPA GLOBAL

Effective date: 20190912

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2021 BY CPA GLOBAL

Effective date: 20200917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2022 BY CPA GLOBAL

Effective date: 20210916

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2023 BY CPA GLOBAL

Effective date: 20220915

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2024 BY CPA GLOBAL

Effective date: 20230914

LAPS Patent lapsed